{"schema_version":"secwatch.filing_event.v1","accession":"0000318154-25-000018","form_type":"8-K","ticker":"AMGN","cik":"0000318154","company_name":"AMGEN INC","filed_at":"2025-05-01T23:59:59+00:00","discovered_at":"2026-05-14T18:02:50.926489+00:00","generated_at":"2026-05-23T01:20:18.052210+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Amgen Q1 beats: revenue $8.1B (+9%), non-GAAP EPS $4.90 (+24%), FCF $1.0B","bullets":["GAAP EPS $3.20 vs -$0.21; includes $800M Otezla intangible impairment.","Non-GAAP EPS $4.90 (+24% YoY) on revenue $8.1B (+9%).","Product sales up 11% with 14% volume growth; 14 products had double-digit growth.","Free cash flow $1.0B vs $0.5B prior year, driven by business performance.","IMDELLTRA sales $81M; Phase 3 confirmatory trial improved overall survival vs chemo."],"urls":{"canonical":"https://secwatch.observer/filing/0000318154-25-000018","json":"https://secwatch.observer/filing/0000318154-25-000018.json","markdown":"https://secwatch.observer/filing/0000318154-25-000018.md","text":"https://secwatch.observer/filing/0000318154-25-000018.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/318154/000031815425000018/0000318154-25-000018-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/318154/000031815425000018/amgn-20250501.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-23T01:20:18.052210+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}